Page last updated: 2024-12-05

iodixanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iodixanol is a non-ionic, iodinated, water-soluble contrast agent. It is a dimer of a triiodinated benzoic acid derivative. Iodixanol is used in diagnostic imaging procedures, such as X-ray, computed tomography (CT), and magnetic resonance imaging (MRI). It is also used in research studies to assess the effects of various factors on cell function and metabolism. Iodixanol is well-tolerated and has a favorable safety profile. It is not metabolized by the body and is excreted in the urine. It is studied because of its high density, which allows for its use in density gradient centrifugation. This technique is used to separate cells, organelles, and other particles based on their density. Iodixanol is also used to study the effects of various stimuli on cell function. For example, it has been used to study the effects of hypoxia on the function of red blood cells.'

iodixanol: dimeric contrast media; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3724
CHEMBL ID1200507
CHEBI ID31705
SCHEMBL ID21546
MeSH IDM0130699

Synonyms (111)

Synonym
5,5'-[(2-hydroxypropane-1,3-diyl)bis(acetylimino)]bis[n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide]
AC-7610
iodixanolum
chebi:31705 ,
BPBIO1_000919
BSPBIO_000835
ccris 7567
1,3-benzenedicarboxamide, 5,5'-((2-hydroxy-1,3-propanediyl)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
visipaque
iodixanolum [latin]
cas-92339-11-2
NCGC00016958-01
PRESTWICK2_000848
NCGC00179408-01
AB00513936
indixanol
DB01249
iodixanol
5,5'-((2-hydroxytrimethylene)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
visipaque (tn)
iodixanol (jan/usp/inn)
D01474
92339-11-2
PRESTWICK0_000848
PRESTWICK1_000848
SPBIO_002756
PRESTWICK3_000848
2-541o-3a
nsc-760069
2-5410-3a
CHEMBL1200507
HMS1570J17
5-[acetyl-[3-[n-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[[3-[[3,5-bis[2,3-bis(oxidanyl)propylcarbamoyl]-2,4,6-tris(iodanyl)phenyl]-ethanoyl-amino]-2-oxidanyl-propyl]-ethanoyl-amino]-n1,n3-bis[2,3-bis(oxidanyl)propyl]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide
5-[acetyl-[3-[n-acetyl-3,5-bis[(2,3-dihydroxypropylamino)-oxomethyl]-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
A844203
HMS2097J17
1,3-benzenedicarboxamide, 5,5'-((2-hydroxy-1,3-propanediyl)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo)-, (16alpha)-
ec 618-837-0
optiprep
visipaque 320
hw8w27htxx ,
5-(acetyl-(3-(acetyl-(3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodophenyl)amino)-2- hydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide; 5,5'-((2-hydroxytrimethylene)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypr
iodixanol [usan:usp:inn:ban]
unii-hw8w27htxx
visipaque 270
nsc 760069
hsdb 8076
nsc760069
pharmakon1600-01503835
dtxcid0025523
tox21_110711
dtxsid2045523 ,
FT-0645028
FT-0627254
iodixanol [usp-rs]
iodixanol [ep monograph]
iodixanol [mart.]
iodixanol [usp impurity]
iodixanol [mi]
iodixanol [orange book]
iodixanol [who-dd]
iodixanol [usp monograph]
iodixanol [usan]
iodixanol [vandf]
iodixanol [inn]
iodixanol [jan]
AKOS015895607
S5218
BRD-A08660406-001-01-8
CCG-213207
SCHEMBL21546
NCGC00179408-03
tox21_110711_1
AB00513936_02
5-{n-[3-(n-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
SR-01000872678-1
SR-01000872678-2
sr-01000872678
optiprep(tm) density gradient medium, used for cell and subcellular organelle isolation
iodixanol; 5,5'-[(2-hydroxypropane-1,3-diyl)bis(acetylimino)]bis[n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide]
HMS3714J17
NBQNWMBBSKPBAY-UHFFFAOYSA-N
5,5'-(2-hydroxypropane-1,3-diyl)bis(acetylazanediyl)bis(n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
visipaque;iodixanolum
lodixanol
Q2419291
BCP11111
optiprep; visipaque; visipaque 270;2-5410-3a
CS-0013137
5,5'-((2-hydroxypropane-1,3-diyl)bis(acetylazanediyl))bis(n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide) ,
5-[acetyl-[3-[n-acetyl-3,5-bis[[(2s)-2,3-dihydroxypropyl]carbamoyl]-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-1-n,3-n-bis[(2s)-2,3-dihydroxypropyl]-2,4,6-triiodobenzene-1,3-dicarboxamide
MS-32198
HY-B1426
5,5-[(2-hydroxy-1,3-propanediyl)bis(acetylimino)]bis[n,n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
EN300-18167324
5-{n-[3-(n-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
iodixanolum (latin)
5-(acetyl-(3-(acetyl-(3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodophenyl)amino)-2-hydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide; 5,5'-((2-hydroxytrimethylene)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypro
v08ab09
1,3-bis(acetylamino)-n,n'-bis
iodixanol (usp-rs)
iodixanol (usan:usp:inn:ban)
iodixanol (usp monograph)
iodixanol (mart.)
iodixanol (ep monograph)
5,5'-((2-hydroxypropane-1,3-diyl)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide)
iodixanol (usp impurity)
a diastereomeric mixture of 5,5'-((2-hydroxy-trimethylene)bis(acetylimino))bis(n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide)
1,3-benzenedicarboxamide, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(acetylimino)]bis[n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
AT38998

Research Excerpts

Overview

Iodixanol (IDX) is a water soluble opacifier widely used in radiographical examinations of blood vessels and neural tissue. It has been suggested as a potential contrast media in acrylic bone cement.

ExcerptReferenceRelevance
"Iodixanol is a non-ionic contrast medium for general vascular use. "( Delayed genital blisters following iodixanol administration.
Xie, H; Yang, XL; Yuan, HL; Yuan, W; Zhang, W, 2017
)
2.17
"Iodixanol (IDX) is a water soluble opacifier widely used in radiographical examinations of blood vessels and neural tissue, and it has been suggested as a potential contrast media in acrylic bone cement. "( Effect of iodixanol particle size on the mechanical properties of a PMMA based bone cement.
Abdulghani, S; Kjellson, F; Lidgren, L; McCarthy, ID; Tanner, KE, 2007
)
2.18
"Iodixanol is a widely used iso-osmolar contrast medium agent. "( Development and validation of an HPLC-UV method for iodixanol quantification in human plasma.
Akhlaghi, F; Chitnis, SD, 2008
)
2.04
"Iodixanol is a new non-ionic, dimeric contrast medium of low osmolality."( Iodixanol in intravenous urography: a comparison of iodixanol 270 mgI/ml, iodixanol 320 mgI/ml and iopamidol 300 mgI/ml (NIOPAM).
Bjartveit, K; Conroy, RM; Long, U; Masterson, J; Sheppick, A, 1994
)
2.45
"Iodixanol is a new nonionic dimer, isotonic with blood at all concentrations. "( A double-blind study comparing safety, tolerability and efficacy of iodixanol 320 mgI/ml and ioxaglate 320 mgI/ml in cerebral arteriography.
De Greef, D; Grynne, BH; Palmers, Y; Put, E; Smits, J, 1993
)
1.96
"Iodixanol is a new nonionic, dimeric contrast medium. "( Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects.
Berg, KJ; Brodahl, U; Endresen, K; Kløw, NE; Kristoffersen, DT; Laake, B; Levorstad, K; Lundby, B; Simonsen, S; Tofte, AJ, 1993
)
3.17
"Iodixanol is a new non-ionic, dimeric contrast medium (CM) which is formulated to be isotonic with blood in all clinically relevant concentrations. "( Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide.
Berg, KJ; Eide, H; Nossen, JO; Pugh, ND; Ruttley, MS; Sissons, GR, 1993
)
3.17
"Iodixanol, which is an isotonic nonionic dimer supplemented with NaCl and CaCl(2), is as well tolerated as iohexol during free coronary flow."( Cardiac electrophysiology, arrhythmogenic mechanisms and roentgen contrast media.
Jacobsen, EA; Klow, NE; Pedersen, HK; Refsum, H, 1995
)
1.01
"Iodixanol (Visipaque) is a new nonionic roentgen contrast medium intended for general use. "( Synthesis and characterization of iodixanol.
Dugstad, H; Gacek, M; Hagen, E; Homestad, OM; Larsen, A; Priebe, H; Sjogren, CE; Thomassen, T, 1995
)
2.01
"Iodixanol itself is an amorphorus and hygroscopic solid which is freely soluble in water."( Physicochemical properties of iodixanol.
Eivindvik, K; Sjogren, CE, 1995
)
1.3
"Iodixanol (Visipaque) is an isotonic, electrolyte-balanced roentgen contrast medium for intravascular use. "( Formulation, stability and compatibility of iodixanol.
Aars, EV; Eivindvik, K, 1995
)
2
"Iodixanol is a relatively new nonionic dimeric contrast medium."( Effect of iodixanol on in vitro bleeding time.
Gabriel, DA; Melton, LG; Muga, KM, 1996
)
1.42
"Iodixanol is a newly developed dimeric, ratio 6 radiographic contrast medium formulated to be isotonic to plasma in all concentrations by the balanced addition of electrolytes."( Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent.
Andrew, E; Fountaine, H; Grynne, B; Harnish, P, 1996
)
1.28
"Iodixanol is a safe and effective nonionic, isotonic contrast medium that may offer clinical advantages."( Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent.
Andrew, E; Fountaine, H; Grynne, B; Harnish, P, 1996
)
2
"Iodixanol is a new nonionic agent with the added attribute of being isosmolar to blood and having less than half the osmolality of iohexol."( A randomized comparison of iodixanol and iohexol in adult intracranial computed tomography scanning.
Grossman, RI; Modic, MT, 1996
)
1.31
"Iodixanol is a new isosmotic hexa-iodinated nonionic contrast agent being evaluated for intravascular use."( Comparison of iodixanol and ioxaglate for adult aortography and renal/visceral angiography: a phase III clinical trial.
Bergh, J; Eckard, DA; Leef, J; Parsa, MB; Redick, ML; Rosenblum, JD; Siegel, EL, 1996
)
1.38
"Iodixanol is an iso-osmolal nonionic dimeric hydrophilic contrast agent. "( Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium.
Goa, KL; Spencer, CM, 1996
)
3.18
"Iodixanol is a new, nonionic, iodinated density gradient medium which has an advantage over other similar media in that it rapidly forms self-generated gradients in vertical or near-vertical rotors. "( Dissection of hepatic receptor-mediated endocytic pathways using self-generated gradients of iodixanol (Optiprep).
Billington, D; Graham, JM; Jackson, AP; Maltby, PJ, 1998
)
1.96
"Iodixanol is a new nonionic dimer, isotonic with blood at all clinically relevant concentrations. "( Iodixanol in cerebral computed tomography: a randomized, double-blind, phase-III, parallel study with iodixanol and iohexol.
Doerfler, A; Fiebach, J; Forsting, M; Henseke, P; Sartor, K; Wanke, I, 1999
)
3.19
"Iodixanol is a new contrast agent that is isotonic at all clinically useful iodine concentrations. "( Studies of iodixanol in the rabbit lung and peritoneum.
Bugaieski, E; Cohen, MD; Davenport, D; Hanna, MP; Heifetz, SA, 1999
)
2.14
"Iodixanol (Visipaque) is a dimeric, non-ionic iodinated contrast medium that is isotonic with blood at all clinically relevant concentrations. "( Iodixanol in paediatric gastrointestinal imaging: safety and efficacy comparison with iohexol.
Carty, HM; Friis, M; Kampenes, VB; Klaveness, AJ; Petersen, KK; Sprigg, A; Stake, G; Wright, NB, 2002
)
3.2
"Iodixanol is reported to be a safe contrast medium that causes no lung injury when instilled intratracheally."( Lodixanol inhibits exogenous surfactant therapy in rats with acute respiratory distress syndrome.
den Heeten, GJ; Haitsma, JJ; Kesecioglu, J; Lachmann, B; Schultz, MJ, 2002
)
1.04
"Iodixanol is a non-ionic dimeric CM which can be made isotonic with blood at iodine concentrations up to 400 mg/ml."( The effect of iodixanol, a new isotonic contrast agent, on femoral blood flow in man.
Pugh, ND; Ruttley, M; Sissons, GR, 1992
)
1.37
"Iodixanol is a new, nonionic, dimeric contrast medium which, in concentrations appropriate for radiographic use, is hypotonic with respect to plasma. "( The effects of iodixanol and iopamidol on hemodynamic and cardiac electrophysiologic parameters in vitro and in vivo.
Bailey, DM; Buchholz, RA; Clas, DM; Dundore, RL; Ezrin, AM; Harnish, PP; Lee, KC; Roth, GM; Silver, PJ; van Aller, G, 1991
)
2.08

Effects

Iodixanol has an osmolality less than half that of monomeric, nonionic equivalent contrast media such as iohexol at equivalent iodine concentrations. It is isosmotic to blood.

Iodixanol has an osmolality less than half that of monomeric, nonionic equivalent contrast media such as iohexol at equivalent iodine concentrations. It is safer and has less effect on patients' serum creatinine levels.

ExcerptReferenceRelevance
"Iodixanol has an osmolality less than half that of monomeric, nonionic contrast media such as iohexol at equivalent iodine concentrations and is isosmotic to blood."( Phase III clinical trial comparing iodixanol and iohexol in cerebral angiography.
Hecht, ST; Nemzek, WR; Newberry, PD; Poirier, VC, 1996
)
1.29
"Iodixanol has an osmolality less than half that of monomeric, nonionic equivalent contrast media."( Iodixanol in excretory urography: initial clinical experience with a nonionic, dimeric (ratio 6:1) contrast medium. Work in progress.
Gavant, ML; Siegle, RL, 1992
)
2.45
"Iodixanol is safer and has less effect on patients' serum creatinine levels."( Iopromide and Iodixanol in the Development of Postoperative Contrast Nephropathy in Patients with Renal Insufficiency: A Meta-Analysis.
Duan, Z; Feng, Y; Hu, W; Li, P; Qiu, G; Wang, L; Wang, M; Xu, C; Zhou, H, 2022
)
1.8
"Iodixanol has cryoprotective effects during rat sperm freezing without any toxic effect. "( Post-thaw ATP supplementation enhances cryoprotective effect of iodixanol in rat spermatozoa.
Agca, C; Agca, Y; Hooper, S; Kim, S, 2016
)
2.12
"Iodixanol has no apparent immediate in vitro incompatibility reactions with drugs often used in connection with roentgen contrast examinations."( Formulation, stability and compatibility of iodixanol.
Aars, EV; Eivindvik, K, 1995
)
1.27
"Iodixanol has an osmolality less than half that of monomeric, nonionic contrast media such as iohexol at equivalent iodine concentrations and is isosmotic to blood."( Phase III clinical trial comparing iodixanol and iohexol in cerebral angiography.
Hecht, ST; Nemzek, WR; Newberry, PD; Poirier, VC, 1996
)
1.29
"Iodixanol has elimination in children >6 months of age that is comparable to normal adults."( Iodixanol pharmacokinetics in children.
Ardinger , RH; Epstein, ML; Johnson , WH; Johnson, JA; Leff, RD; Lloyd, TR; Marsters, PA; Slovis, TL; Victorica, BE; Zales, VR,
)
2.3
"Iodixanol has an osmolality less than half that of monomeric, nonionic equivalent contrast media."( Iodixanol in excretory urography: initial clinical experience with a nonionic, dimeric (ratio 6:1) contrast medium. Work in progress.
Gavant, ML; Siegle, RL, 1992
)
2.45

Actions

Iodixanol showed a lower CI-AKI incidence than low-osmolar contrast media (LOCM) It may cause less discomfort than iohexol, in particular when larger volumes of CM are injected.

ExcerptReferenceRelevance
"Iodixanol, showed a lower CI-AKI incidence than low-osmolar contrast media (LOCM)."( Economic evaluation of intravenous iodinated contrast media in Italy.
De Francesco, M; Iannazzo, S; Morana, G; Nayak, A; Ronco, C; Valentino, M; Vandekerckhove, S, 2014
)
1.12
"Iodixanol may cause less discomfort than iohexol, in particular when larger volumes of CM are injected."( Image quality and safety after iodixanol in intravenous urography; a comparison with iohexol.
Almén, T; Bååth, L; Hougens Grynne, B; Kjaersgaard, P; Sundgren, PC; Törnquist, C, 1996
)
1.3
"Iodixanol, with its lower intensity (and possibly frequency) of discomfort, may be a preferred option in these patients."( Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium.
Goa, KL; Spencer, CM, 1996
)
2.46

Treatment

Iodixanol treatment increased the phosphorylation of p38, ERK and cleavage of caspase-3 in LLC-PK1 cells. Co-treatment with α-mangostin (2.5 and 5μM) significantly decreased the levels of Apn A.

ExcerptReferenceRelevance
"Iodixanol treatment of tubules significantly increased the concentration of Apn A (n = 3-5) in the supernatant. "( Diadenosine pentaphosphate modulates glomerular arteriolar tone and glomerular filtration rate.
Carlström, M; Flöge, J; Heintz, B; Jankowski, J; Jankowski, V; Lai, EY; Liu, ZZ; Patzak, A; Sällström, J; Sendeski, MM, 2015
)
1.86
"Iodixanol treatment increased the phosphorylation of p38, ERK and cleavage of caspase-3 in LLC-PK1 cells, which were significantly decreased by co-treatment with α-mangostin (2.5 and 5μM)."( Protective effect of α-mangostin against iodixanol-induced apoptotic damage in LLC-PK1 cells.
Chin, YW; Choi, YO; Jung, K; Kim, KH; Lee, D; Namgung, H; Yamabe, N, 2016
)
1.42

Toxicity

Iodixanol is a safe and effective nonionic, isotonic contrast medium that may offer clinical advantages. Unlike iohexol and ioxaglate, the rate of adverse events after iodixanol administration was essentially the same for normal patients.

ExcerptReferenceRelevance
"The low osmolar, non-ionic X-ray contrast media have shown a lower frequency of adverse events than the older ionic ones."( Safety and tolerability of iodixanol in healthy volunteers with reference to two monomeric X-ray contrast media.
Borch, KW; Jørgensen, NP; Kristiansen, AB; Kristoffersen, DT; Lundby, B; Nossen, JO; Theodorsen, L, 1992
)
0.58
"Selective vertebral angiography was performed in 28 rabbits in order to compare the adverse effects of two monomeric (metrizamide, iohexol) and two dimeric (iodecol, 2-5410-3) non-ionic water-soluble contrast media."( The toxicity of non-ionic water-soluble contrast media in selective vertebral angiography. An experimental study in rabbits with special reference to the difference between monomeric and dimeric compounds.
Aulie, A; Skalpe, IO, 1985
)
0.27
" No remarkable adverse effects on fertility were noted at any dose level."( [Reproductive toxicity of iodixanol, a new non-ionic, iso-tonic contrast medium in rats and rabbits].
Fujikawa, K; Harada, S; Holtz, E; Sakaguchi, Y; Smith, JA; Svendsen, O, 1995
)
0.59
" The LD50 values were estimated to be 17."( [Intravenous single dose toxicity of iodixanol, a new nonionic iso-osmolar contrast medium, in mice, rats and monkeys].
Furuhama, K; Genda, Y; Ishijima, N; Kakihata, K; Nomura, M; Ohno, H; Takahashi, Y; Yamamura, H, 1995
)
0.56
" No clinical signs indicative of a toxic effect of iodixanol were noted."( [Toxicity of iodixanol, a new nonionic iso-osmolar contrast medium, to rats by repeated intravenous administration for 4 weeks with a 4-week recovery period].
Crome, SJ; Furuhama, K; Nomura, M; Ohno, H; Onodera, T, 1995
)
0.91
" Safety was evaluated by recording discomfort and other adverse events, changes in ECG, heart rate and blood pressure, changes in intra-arterial blood pressure and circulation time."( A double-blind study comparing safety, tolerability and efficacy of iodixanol 320 mgI/ml and ioxaglate 320 mgI/ml in cerebral arteriography.
De Greef, D; Grynne, BH; Palmers, Y; Put, E; Smits, J, 1993
)
0.52
" Regarding iodinated contrast media (CM), LD50 tests were used extensively in the past."( Preclinical safety assessment of contrast media: predictive value.
Karlsson, JO, 1996
)
0.29
" Unlike iohexol and ioxaglate, the rate of adverse events after iodixanol administration was essentially the same for normal patients as for patients at increased risk for negative reactions (patients with previous adverse reactions to contrast administration)."( Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent.
Andrew, E; Fountaine, H; Grynne, B; Harnish, P, 1996
)
0.8
"Iodixanol is a safe and effective nonionic, isotonic contrast medium that may offer clinical advantages."( Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent.
Andrew, E; Fountaine, H; Grynne, B; Harnish, P, 1996
)
2
" The incidence of adverse events was similar and low for both contrast media."( Image quality and safety after iodixanol in intravenous urography; a comparison with iohexol.
Almén, T; Bååth, L; Hougens Grynne, B; Kjaersgaard, P; Sundgren, PC; Törnquist, C, 1996
)
0.58
"Iodixanol 270 mg I/ml causes significantly less injection-associated pain during femoral arteriography and is as safe and efficacious as iopromide 300 mg I/ml."( Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide.
Downes, M; Grynne, BH; Justesen, P; Lang, H; Rasch, W; Seim, E,
)
1.78
" Adverse events, including injection associated discomfort, were recorded during and up to 24 h after the examination."( Iodixanol in paediatric excretory urography: efficiency and safety compared to iohexol.
Amar, C; Boscq, M; Chateil, JF; Dacher, J; Garel, C; Hassan, M; Sirinelli, D, 1998
)
1.74
"No serious adverse event occurred in any of the three groups."( Iodixanol in paediatric excretory urography: efficiency and safety compared to iohexol.
Amar, C; Boscq, M; Chateil, JF; Dacher, J; Garel, C; Hassan, M; Sirinelli, D, 1998
)
1.74
" With regards to cell viability, transmonolayer resistance and inulin permeability the radiocontrast agents with reduced osmolality were significantly less toxic than diatrizoate, independent of their ionic strength."( Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro.
Haller, C; Schick, CS, 1999
)
0.3
" Safety was assessed by blood tests, clinical examinations and recording of subjective adverse events (AE)."( A new liposomal liver-specific contrast agent for CT: first human phase-I clinical trial assessing efficacy and safety.
Berg, A; Børseth, A; Höglund, P; Kloster, Y; Leander, P, 2001
)
0.31
" The frequency of adverse events was lower for patients receiving iodixanol."( Iodixanol in paediatric gastrointestinal imaging: safety and efficacy comparison with iohexol.
Carty, HM; Friis, M; Kampenes, VB; Klaveness, AJ; Petersen, KK; Sprigg, A; Stake, G; Wright, NB, 2002
)
1.99
" No difference was found between the groups regarding the frequency of patients having adverse reactions (5."( Pain in femoral arteriography. A double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mgI/ml and the low-osmolar iomeprol 300 mgI/ml in 9 European centers.
Batakis, O; Fog, A; Manke, C; Marcus, C; Page, A; Puey, J, 2003
)
0.53
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" This contrast agent has the lowest rates of systemic and renal adverse events."( Renal safety of iodixanol.
McCullough, PA, 2006
)
0.68
"To evaluate the incidence of adverse events with the universal use of iodixanol for computed tomography (CT) and compare it with periods when iohexol was used exclusively."( Adverse events with universal use of iodixanol for CT: comparison with iohexol.
Ho, AL; O'Malley, ME; Tomlinson, GA,
)
0.64
" Immediate and delayed adverse events were seen in 76 and 40 patients (0."( Adverse events with universal use of iodixanol for CT: comparison with iohexol.
Ho, AL; O'Malley, ME; Tomlinson, GA,
)
0.4
" However, the incidence of immediate and delayed adverse events was significantly higher with iodixanol than iohexol."( Adverse events with universal use of iodixanol for CT: comparison with iohexol.
Ho, AL; O'Malley, ME; Tomlinson, GA,
)
0.62
" Adverse events occurred in 1/91 (1."( Enhancement and safety of iomeprol-400 and iodixanol-320 in patients undergoing abdominal multidetector CT.
Bonomo, L; Catalano, C; Chen, KM; Dore, R; Grazioli, L; Romano, L; Vanzulli, A; Xu, JR, 2009
)
0.62
"The relationship of contrast-induced nephropathy (CIN) to long-term adverse events (AEs) is controversial."( Contrast-induced nephropathy and long-term adverse events: cause and effect?
Barrett, BJ; Doucet, S; Gelormini, JL; Katholi, RE; Labinaz, M; Mehran, R; Natarajan, MK; Sharma, SK; Solomon, RJ; Staniloae, CS, 2009
)
0.35
" The secondary endpoints are absolute and relative increases in sCr of at least 50%, thrombolysis in myocardial infarction (TIMI) perfusion grade, and major adverse cardiac events at 1, 6, and 12 months."( The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Limbruno, U; Picchi, A; Pierli, C, 2010
)
0.36
"Iodinated radiographic contrast media are considered safe diagnostic drugs with a low incidence of adverse drug reactions."( Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations.
Häussler, MD, 2010
)
0.64
"To determine prospectively the incidence and nature of immediate and delayed adverse drug reactions occurring after administration of iodixanol for contrast-enhanced computed tomography (CT) in routine practice in nonselected patients, and to assess patient comfort (pain and sensations of heat or coldness)."( Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations.
Häussler, MD, 2010
)
0.85
" Patients were asked to report immediate (during the visit) or delayed (occurring up to 7 days after administration of iodixanol) adverse reactions; those deemed related or possibly related to iodixanol were documented on a standardized adverse drug reaction form."( Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations.
Häussler, MD, 2010
)
0.85
" Adverse drug reactions were reported in 70 patients (0."( Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations.
Häussler, MD, 2010
)
0.64
" There were no unexpected serious adverse drug reactions, and patient discomfort during administration was mild or absent in most patients."( Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations.
Häussler, MD, 2010
)
0.64
" To assess the toxic effects of non-ionic CM on the glomerular and aortic endothelial cells, iopromide and iodixanol, two kinds of representative non-ionic CM, were used for the in vivo study."( Toxic effects of a high dose of non-ionic iodinated contrast media on renal glomerular and aortic endothelial cells in aged rats in vivo.
Chen, B; Chen, L; Jia, E; Jia, Q; Li, C; Tao, Z; Wang, L; Xu, Z; Yang, Z; Zhao, Y; Zhu, T, 2011
)
0.58
"SRFA allowed for efficient, reliable, and safe ablation of large-volume liver disease."( Stereotactic radiofrequency ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance.
Bale, R; Haidu, M; Schullian, P; Widmann, G, 2012
)
0.38
" We found: (a) frequency domain imaging is safe in the porcine model using histology as an endpoint; (b) the addition of a viscous contrast (iodixonal) to saline is superior for lumen clearance compared to saline alone; (c) hand injection, 4 ml/sec, and 6 ml/sec power injection all provided similar vessel wall clearance; (d) the anticipated loss of vessel wall visualisation with left main injection (due to half the injectate in the non-imaged vessel) was not evident in proximal and middle coronary artery OCT catheter positions."( Safety and efficacy of frequency domain optical coherence tomography in pigs.
Bailey, SR; Banas, C; Feldman, MD; Glynn, T; Jabara, R; Kemp, N; Li, X; Michalek, JE; Ouyang, Y; Sims, D; Villard, JW, 2011
)
0.37
"Frequency domain OCT is safe and efficacious in the porcine model."( Safety and efficacy of frequency domain optical coherence tomography in pigs.
Bailey, SR; Banas, C; Feldman, MD; Glynn, T; Jabara, R; Kemp, N; Li, X; Michalek, JE; Ouyang, Y; Sims, D; Villard, JW, 2011
)
0.37
" to determine the extent of preventive measures for risk reduction of adverse drug reactions after contrast-enhanced CT examinations."( Post-marketing surveillance of the safety profile of iodixanol in the outpatient CT setting: a prospective, multicenter, observational study of patient risk factors, adverse reactions and preventive measures in 9953 patients.
Müller, FH, 2014
)
0.65
" Patient characteristics, aspects of iodixanol administration, and adverse events with an at least "possible" relationship were documented on a standardized case report form (CRF) and were evaluated up to seven days after contrast medium administration."( Post-marketing surveillance of the safety profile of iodixanol in the outpatient CT setting: a prospective, multicenter, observational study of patient risk factors, adverse reactions and preventive measures in 9953 patients.
Müller, FH, 2014
)
0.92
" Adverse drug reactions, mainly hypersensitivity reactions, occurred in 77 patients (0."( Post-marketing surveillance of the safety profile of iodixanol in the outpatient CT setting: a prospective, multicenter, observational study of patient risk factors, adverse reactions and preventive measures in 9953 patients.
Müller, FH, 2014
)
0.65
" The rate of acute and delayed adverse reactions was low."( Post-marketing surveillance of the safety profile of iodixanol in the outpatient CT setting: a prospective, multicenter, observational study of patient risk factors, adverse reactions and preventive measures in 9953 patients.
Müller, FH, 2014
)
0.65
"• Low rate of acute and late adverse drug reactions to iodixanol."( Post-marketing surveillance of the safety profile of iodixanol in the outpatient CT setting: a prospective, multicenter, observational study of patient risk factors, adverse reactions and preventive measures in 9953 patients.
Müller, FH, 2014
)
0.9
" However, little is documented about the effects of contrast on hemodynamics in heart failure patients or the prognostic value of baseline and changes in hemodynamics for predicting subsequent adverse events."( Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.
Denardo, SJ; O'Connor, CM; Schmalfuss, CM; Tcheng, JE; Vock, DM; Young, GD, 2016
)
0.43
" One-year Kaplan-Meier estimates of adverse event-free survival (death, heart failure hospitalization, and rehospitalization) were generated, grouping patients by baseline measures of pulmonary capillary wedge pressure (PCWP) and cardiac index (CI), and by changes in those measures after contrast administration."( Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.
Denardo, SJ; O'Connor, CM; Schmalfuss, CM; Tcheng, JE; Vock, DM; Young, GD, 2016
)
0.43
" Calculating baseline PCWP with change in CI after contrast predicts adverse events and increases the predictive value of existing models."( Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.
Denardo, SJ; O'Connor, CM; Schmalfuss, CM; Tcheng, JE; Vock, DM; Young, GD, 2016
)
0.43
"The relative incidence of long-term adverse effects between low-osmolar contrast media (LOCM) and iso-osmolar contrast media (IOCM) after coronary angiography is still unclear."( Long-Term Adverse Effects of Low-Osmolar Compared With Iso-Osmolar Contrast Media After Coronary Angiography.
Chang, D; Ju, S; Lu, CQ; Tang, A; Wang, YC; Zhang, SJ, 2016
)
0.43
" Treatment-emergent adverse events were similar between groups (iodixanol 18."( Randomized, Double-Blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography - The COMFORT II Trial.
Lim, L; Lonjedo Vicent, E; Macho, J; Martínez-Rodrigo, JJ; Rosenberg, C; Todoran, TM, 2017
)
0.92
" The secondary endpoints were the mean peak SCr increase within 72 h after receiving CM and major adverse renal events (SCr increased by two times after 30 days, the need for dialysis treatment, rehospitalization for acute renal failure, or kidney-related death) during hospitalization and within 30 day postdischarge."( Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy.
Che, WQ; Chen, Y; Dong, H; Gao, RL; Jiang, XJ; Peng, M; Xiong, HL; Xu, B; Yang, YJ; Zou, YB, 2018
)
0.81
"609] with doubling of SCr; no other adverse renal events were observed."( Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy.
Che, WQ; Chen, Y; Dong, H; Gao, RL; Jiang, XJ; Peng, M; Xiong, HL; Xu, B; Yang, YJ; Zou, YB, 2018
)
0.81
"Image-guided MWA appears to be a safe and effective treatment regardless of nephrometry score and tumor location with high technical success, low recurrence, and complication rates."( The effect of tumor size and location on efficacy and safety of US- and CT- guided percutaneous microwave ablation in renal cell carcinomas.
Afshari Mirak, S; Ahuja, P; Lu, DS; Mohammadian Bajgiran, A; Pantuck, A; Raman, SS; Shakeri, S; Sisk, A, 2019
)
0.51
" Intravenous provocation with a skin test-negative RCM is safe and enables identification of a tolerated alternative RCM."( Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation.
Behle, V; Brockow, K; Stoevesandt, J; Trautmann, A,
)
0.13
"One serious adverse event (anaphylaxis) occurred in a patient with known allergy to iodine-containing contrast agents (1%)."( Intrathecal Use of Gadobutrol for Glymphatic MR Imaging: Prospective Safety Study of 100 Patients.
Edeklev, CS; Eide, PK; Gjertsen, Ø; Halvorsen, M; Løvland, G; Nedregaard, B; Ringstad, G; Sletteberg, R; Vatnehol, SAS, 2019
)
0.51
"Intrathecal administration of gadobutrol in conjunction with iodixanol for glymphatic MR imaging is safe and feasible."( Intrathecal Use of Gadobutrol for Glymphatic MR Imaging: Prospective Safety Study of 100 Patients.
Edeklev, CS; Eide, PK; Gjertsen, Ø; Halvorsen, M; Løvland, G; Nedregaard, B; Ringstad, G; Sletteberg, R; Vatnehol, SAS, 2019
)
0.76
"This study was aimed at comparing the adverse drug reactions (ADRs) arising from the use of iodinated contrast medium (ICM) and gadolinium-based contrast media (GBCM), and to provide a basis for the clinical selection of contrast media."( Clinical safety evaluation of contrast agents based on real-world evidence.
Huang, D; Huang, Y; Jiang, C; Jiang, X; Li, J; Lin, J, 2021
)
0.62
"5% dextrose dialysis solution is chemically stable, meeting the criteria set forth in the standards and guidelines of the US Pharmacopeia and the Institute of Safe Medication Practices."( Compatibility and stability of non-ionic iodinated contrast media in peritoneal dialysis solution and safe practice considerations for CT peritoneography.
Badugu, SK; Crabtree, JH; Gellens, ME; Kaushal, A; Mancini, A; Rappai, J, 2023
)
0.91

Pharmacokinetics

Iodixanol has fewer cardiovascular effects, causes less renal damage and is associated with similar or smaller changes to the blood-brain barrier and neurological function.

ExcerptReferenceRelevance
"The pharmacokinetic properties of the x-ray contrast medium, iodixanol, a new nonionic dimer, were investigated in a phase I study including 40 healthy male volunteers."( Human pharmacokinetics of iodixanol.
Andrew, E; Haider, T; Hals, PA; Langseth-Manrique, K; Svaland, MG, 1992
)
0.83
"To document the safety of iodixanol and to assess its pharmacokinetic properties, extensive tests have been performed."( Preclinical pharmacokinetics and general toxicology of iodixanol.
Blazak, WF; Furuhama, K; Heglund, IF; Holtz, E; Michelet, AA, 1995
)
0.84
" Indeed, pharmacodynamic studies indicate that iodixanol has fewer cardiovascular effects, causes less renal damage and is associated with similar or smaller changes to the blood-brain barrier and neurological function when compared with nondimeric nonionic contrast media."( Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium.
Goa, KL; Spencer, CM, 1996
)
1.99
" These data were used to calculate pharmacokinetic parameters such as half-lives, mean residence times, and areas under the curve with a computer program."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" The computer program allowed for excellent fitting curves to the measured attenuation values and for subsequent calculation of pharmacokinetic parameters."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
"The pharmacokinetic parameters evaluated might be useful in the optimization of dosing and scanning parameters of the abdomen for ultrafast and helical CT."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" The primary pharmacokinetic endpoint was the terminal elimination rate constant (kel)."( Iodixanol pharmacokinetics in children.
Ardinger , RH; Epstein, ML; Johnson , WH; Johnson, JA; Leff, RD; Lloyd, TR; Marsters, PA; Slovis, TL; Victorica, BE; Zales, VR,
)
1.57

Compound-Compound Interactions

100 kVp and Iodixanol (270 mg I/ml) combined with iDose(4) -4 iterative reconstruction technique for CT angiography of lower extremities. Image quality could meet the requirement for clinical diagnosis, the radiation dose and the volume of contrast medium could be lowered.

ExcerptReferenceRelevance
"The purpose of this study was to assess whether portal vein embolization (PVE) using a nitinol vascular plug in combination with histoacryl glue and iodinized oil minimizes the risk of nontarget embolization while obtaining good levels of future liver remnant (FLR) hypertrophy."( Portal vein embolization using a nitinol plug (Amplatzer vascular plug) in combination with histoacryl glue and iodinized oil: adequate hypertrophy with a reduced risk of nontarget embolization.
Bent, CL; Fotheringham, T; Low, D; Matson, MB; Renfrew, I, 2009
)
0.35
"To evaluate the feasibility of CT angiography of lower extremities by using 100 kVp as tube voltage and Iodixanol(270 mg I/ml) as contrast medium combined with iDose(4) iterative reconstruction technique."( [Applied research of CT angiography of lower extremities by using 100 kVp and iodixanol(270 mg I/ml) combined with iDose(4) iterative reconstruction technique].
Chen, B; Cheng, J; He, H; Kong, Q; Xiong, S; Xu, L; Xu, X; Yan, Z, 2015
)
0.86
"Using 100 kVp and Iodixanol (270 mg I/ml) combined with iDose(4) -4 iterative reconstruction technique for CT angiography of lower extremities, the image quality could meet the requirement for clinical diagnosis, the radiation dose and the volume of contrast medium could be lowered."( [Applied research of CT angiography of lower extremities by using 100 kVp and iodixanol(270 mg I/ml) combined with iDose(4) iterative reconstruction technique].
Chen, B; Cheng, J; He, H; Kong, Q; Xiong, S; Xu, L; Xu, X; Yan, Z, 2015
)
0.98
"BACKGROUND This study is to investigate the feasibility of low iodine concentration contrast material (CM) combined with low tube voltage and adaptive statistical iterative reconstruction (ASIR) in renal computed tomography angiography (CTA)."( Low-Dose Scanning Technology Combined with Low-Concentration Contrast Material in Renal Computed Tomography Angiography (CTA): A Preliminary Study.
Fan, J; He, J; Li, W; Liu, S; Sheng, H; Shi, H; Sun, H, 2017
)
0.46

Bioavailability

Iodixanol in doses typically used for coronary interventions constricts DVR, intensifies angiotensin II-induced constriction, and reduces bioavailability of NO. Decreased nitric oxide bioavailability and increased concentration of superoxide explain the increased tone and reactivity in arterioles perfused with iodixanol.

ExcerptReferenceRelevance
" Moreover, iodixanol decreased NO bioavailability by more than 82%."( Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy.
Cao, C; Pallone, TL; Patzak, A; Persson, AE; Persson, PB; Sendeski, M, 2009
)
2.19
"Iodixanol in doses typically used for coronary interventions constricts DVR, intensifies angiotensin II-induced constriction, and reduces bioavailability of NO."( Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy.
Cao, C; Pallone, TL; Patzak, A; Persson, AE; Persson, PB; Sendeski, M, 2009
)
3.24
" Fluorescence of 3-amino-4-(N-methylamino)-2',7'-difluorofluorescein (DAF-FM) and dihydroethidium (DHE) were used for quantification of nitric oxide bioavailability and superoxide concentration, respectively."( Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate.
Lai, EY; Liu, ZZ; Patzak, A; Perlewitz, A; Persson, PB; Sendeski, MM; Viegas, VU, 2012
)
0.38
" Decreased nitric oxide bioavailability and increased concentration of superoxide explain the increased tone and reactivity in afferent arterioles perfused with iodixanol."( Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate.
Lai, EY; Liu, ZZ; Patzak, A; Perlewitz, A; Persson, PB; Sendeski, MM; Viegas, VU, 2012
)
0.58
" CM increased superoxide concentration and reduced nitric oxide bioavailability in TAL."( Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback.
Cantow, K; Liu, R; Liu, ZZ; Lu, Y; Nikitina, T; Patzak, A; Perlewitz, A; Persson, PB; Schmerbach, K; Seeliger, E; Sendeski, MM, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Groups of 10 male and 10 female Crl: CD (SD) BR rats were given iodixanol, a radiographic contrast medium, by intravenous injection at dosage levels of 30, 100 or 300 mgI/kg/day for four weeks to evaluate its toxicity. Only one patient showed renal failure, one week after dosing with iodix ethanol.

ExcerptRelevanceReference
" These signs disappeared mostly by 8 days after dosing in surviving animals."( [Intravenous single dose toxicity of iodixanol, a new nonionic iso-osmolar contrast medium, in mice, rats and monkeys].
Furuhama, K; Genda, Y; Ishijima, N; Kakihata, K; Nomura, M; Ohno, H; Takahashi, Y; Yamamura, H, 1995
)
0.56
"Groups of 10 male and 10 female Crl: CD (SD) BR rats were given iodixanol, a radiographic contrast medium, by intravenous injection at dosage levels of 30, 100 or 300 mgI/kg/day for four weeks to evaluate its toxicity."( [Toxicity of iodixanol, a new nonionic iso-osmolar contrast medium, to rats by repeated intravenous administration for 4 weeks with a 4-week recovery period].
Crome, SJ; Furuhama, K; Nomura, M; Ohno, H; Onodera, T, 1995
)
0.9
"Groups of 3 male and 3 female wild-caught cynomolgus monkeys were given iodixanol, a radiographic contrast medium, by intravenous injection at dosage levels of 100, 300 or 1,000 mgI/kg/day for four weeks to evaluate its toxicity."( [Toxicity of iodixanol, a new nonionic iso-osmolar contrast medium, to cynomolgus monkeys by repeated intravenous administration for 4 weeks with a 4-week recovery period].
Crome, SJ; Furuhama, K; Genda, Y; Nomura, M; Ohno, H; Onodera, T, 1995
)
0.89
" Further, no toxic effects on pups were seen when rats were dosed during the lactation period."( Preclinical pharmacokinetics and general toxicology of iodixanol.
Blazak, WF; Furuhama, K; Heglund, IF; Holtz, E; Michelet, AA, 1995
)
0.54
" New dosage regimens also could be simulated successfully."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
"The pharmacokinetic parameters evaluated might be useful in the optimization of dosing and scanning parameters of the abdomen for ultrafast and helical CT."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" Efficacy was assessed using single-slice CT of the abdomen and evaluated by dose-response attenuation curves over time in liver, spleen, and abdominal vessels."( A new liposomal liver-specific contrast agent for CT: first human phase-I clinical trial assessing efficacy and safety.
Berg, A; Børseth, A; Höglund, P; Kloster, Y; Leander, P, 2001
)
0.31
" Accumulating evidence suggests that the use of iso-osmolar contrast agents in conjunction with other proven measures, especially adequate intravenous hydration and contrast dosage limitation, can reduce the morbidity and mortality associated with CIN."( Recent clinical trials of iodixanol.
Davidson, CJ; Erdogan, A, 2003
)
0.62
" Seventy patients matched for BMI who had previously undergone routine coronary CT angiography with a fixed contrast material dosage of 80 mL at 5 mL/s served as the reference group."( Low-dose coronary CT angiography with prospective ECG triggering: validation of a contrast material protocol adapted to body mass index.
Burger, IA; Burkhard, N; Gaemperli, O; Herzog, BA; Husmann, L; Kaufmann, PA; Valenta, I, 2009
)
0.35
" Subsequently, Han Wistar rats (8 per group) received an intravenous injection of iso-osmolar CA (iodixanol) or low-osmolar CA (iopromide) at a dosage of 4 gI/kg body weight."( Changes of renal water diffusion coefficient after application of iodinated contrast agents: effect of viscosity.
Hütter, J; Jost, G; Lengsfeld, P; Lenhard, DC; Pietsch, H; Sieber, MA, 2011
)
0.59
" Only one patient showed renal failure, one week after dosing with iodixanol."( Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
Chen, Y; Fu, G; Gao, C; Gao, W; He, B; He, Q; Hu, S; Liu, H; Liu, S; Liu, Y; Qi, X; Qiu, C; Su, X; Wang, J; Wang, L; Wang, M; Yang, P; Zhao, R; Zheng, X; Zheng, Y; Zhou, S, 2012
)
0.89
" The CAs were administered intravenously at a dosage of 4 g iodine/kg body weight."( The effect of iodinated contrast agent properties on renal kinetics and oxygenation.
Frisk, AL; Jost, G; Lengsfeld, P; Lenhard, DC; Pietsch, H, 2013
)
0.39
" This makes it potentially feasible to automatically individualize CM dosage by CT."( Automatic individualized contrast medium dosage during hepatic computed tomography by using computed tomography dose index volume (CTDI(vol)).
Aspelin, P; Björk, J; Brismar, TB; Cederlund, K; Nyman, U; Svensson, A, 2014
)
0.4
" The computed tomography dose index volume (CTDIvol), dose length product (DLP), effective dose (ED), and total iodine dosage were calculated and compared."( The combination of a reduction in contrast agent dose with low tube voltage and an adaptive statistical iterative reconstruction algorithm in CT enterography: Effects on image quality and radiation dose.
Feng, C; Hu, D; Hu, X; Li, A; Li, Z; Zhu, D; Zou, X, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.00750.006038.004119,952.5996AID1159521
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency17.37680.01237.983543.2770AID1645841
Cellular tumor antigen p53Homo sapiens (human)Potency0.00360.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,133)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (0.88)18.7374
1990's194 (17.12)18.2507
2000's374 (33.01)29.6817
2010's495 (43.69)24.3611
2020's60 (5.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.57 (24.57)
Research Supply Index7.26 (2.92)
Research Growth Index6.06 (4.65)
Search Engine Demand Index88.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials201 (16.41%)5.53%
Reviews44 (3.59%)6.00%
Case Studies68 (5.55%)4.05%
Observational12 (0.98%)0.25%
Other900 (73.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]